14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
PBJ vs PJP: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PBJ vs PJP. Trailing 12-month operating profitability (PBJ N/A vs PJP N/A) and valuation multiples (PBJ N/M vs PJP N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ PBJ vs PJP Key Questions & Quantitative Answers
As of Nov 16, 2026, Invesco Pharmaceuticals ETF (PJP) is the stronger overall head-to-head candidate over Invesco Food & Beverage ETF (PBJ) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). PBJ carries a Unified Composite Score of 47.7/100 (HOLD) at $48.07 (N/M Forward P/E, N/A operating margin), whereas PJP carries 50.1/100 (HOLD) at $130.10 (N/M Forward P/E, N/A operating margin). Technically, PBJ sits in a Neutral phase (RSI 54.0, UNCLASSIFIED options structure) and PJP sits in a Neutral phase (RSI 58.4, UNCLASSIFIED options structure).
PBJ and PJP split Growth & Scale metrics: PBJ posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with PJP at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PBJ generates N/A in USD-normalized revenue versus N/A for PJP. In operating R&D and SG&A reinvestment, PBJ deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PJP.
PBJ and PJP trade at balanced relative valuation multiples. PBJ trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PJP trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PBJ (N/A ROE) versus PJP (N/A ROE) capital efficiency.
In options market volatility and institutional positioning, PBJ carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.06β · 22% Vol realized risk). By comparison, PJP carries 20.7% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.45β · 23% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.